Gaurav Marwaha, MD
Radiation Oncology · Chicago, ILNPI 1669798062
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,500 of the $5,683 with a category attached, or 79.2%. AstraZeneca accounts for 97.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $5,567 and has fallen 98.4% since, to $86 in 2025.
Across 17 payments — averaging $334.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Janssen Research & Development, LLC$86
- Novocure Inc.$29
- Varian Medical Systems, Inc.$29
Across 7 payments — averaging $82,996 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$581K
What the payments were for
- Consulting fees$4,50079%
- Travel & lodging$68912%
- Food & beverage$4939%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $5,538 |
| Janssen Research & Development, LLC | 1 | $86 |
| Novocure Inc. | 1 | $29 |
| Varian Medical Systems, Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$759
How this compares
$5,683 in reported general payments places this provider in the 85th percentile of 242 radiation oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 14 | $173 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Chicago
- Sean PitrodaChicago$103K
- Aditya JulooriChicago$73K
- Steven ChmuraChicago$59K
- William SmallChicago$54K
- Ken TatebeChicago$42K
- Sean SachdevChicago$34K
- Yasmin HasanChicago$18K
- Ralph WeichselbaumChicago$11K
- Tarita ThomasChicago$8K
- Dian WangChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.